<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081055</url>
  </required_header>
  <id_info>
    <org_study_id>Mesoblast</org_study_id>
    <secondary_id>UCLA-0303036</secondary_id>
    <secondary_id>CDR0000358809</secondary_id>
    <nct_id>NCT00081055</nct_id>
  </id_info>
  <brief_title>OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies</brief_title>
  <official_title>A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of OTI-010 in Subjects Who Receive HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mesoblast International Sàrl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mesoblast, Ltd.</source>
  <brief_summary>
    <textblock>
      RATIONALE: OTI-010 may be effective for graft-versus-host disease prophylaxis (prevention) in&#xD;
      patients who are undergoing donor peripheral stem cell transplantation for hematologic&#xD;
      malignancies (cancer of the blood or bone marrow).&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well OTI-010 works in preventing&#xD;
      graft-versus-host disease in patients who are undergoing donor peripheral stem cell&#xD;
      transplantation for hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the safety and efficacy of OTI-010 vs placebo as graft-versus-host disease&#xD;
           prophylaxis in patients with hematologic malignancies undergoing HLA-identical sibling&#xD;
           matched peripheral blood stem cell transplantation.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are stratified according to age (18 to 34 vs 35 to 55) and donor/recipient gender (female&#xD;
      donor/male recipient vs female donor/female recipient vs male donor/female recipient vs male&#xD;
      donor/male recipient).&#xD;
&#xD;
        -  Conditioning regimen: Patients receive cyclophosphamide IV once daily on days -5 and -4&#xD;
           and undergo total body irradiation twice daily on days -3 to -1 OR busulfan IV over 2&#xD;
           hours every 6 hours on days -7 to -4 and cyclophosphamide IV once daily on days -3 and&#xD;
           -2.&#xD;
&#xD;
        -  Graft-versus-host disease prophylaxis: Patients receive methotrexate IV on days 1, 3, 6,&#xD;
           and 11. Patients also receive cyclosporine orally or IV (over 1-4 hours) twice daily&#xD;
           beginning on day -1 and continuing for at least 6 months followed by a taper until 1&#xD;
           year after transplantation.&#xD;
&#xD;
        -  OTI-010 therapy: Patients are randomized to 1 of 3 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive placebo IV 4 hours before peripheral blood stem cell&#xD;
                transplantation (PBSCT) on day 0.&#xD;
&#xD;
             -  Arm II: Patients receive OTI-010 IV 4 hours before PBSCT on day 0.&#xD;
&#xD;
             -  Arm III: Patients receive a higher dose of OTI-010 IV 4 hours before PBSCT on day&#xD;
                0.&#xD;
&#xD;
        -  Allogeneic stem cell transplantation: Patients undergo allogeneic PBSCT on day 0.&#xD;
&#xD;
      Patients are followed at 18 weeks, at 6, 9, and 12 months, every 6 months for 1 year, and&#xD;
      then annually for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 99 patients (33 per treatment arm) will be accrued for this&#xD;
      study within 5 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute GVHD grade II-IV of skin, liver and gut (stomach to rectum) through Day 84 post-PBSC transplantation</measure>
    <time_frame>Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by infusional toxicity, relapse nd survival, formation of potential ectopic tissue foci</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous expanded mesenchymal stem cells OTI-010</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following hematologic malignancies:&#xD;
&#xD;
               -  Acute lymphoblastic leukemia, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In first or second remission&#xD;
&#xD;
                    -  In early first or second relapse*&#xD;
&#xD;
               -  Acute myeloid leukemia, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In first or second remission&#xD;
&#xD;
                    -  In early first or second relapse*&#xD;
&#xD;
               -  Chronic myelogenous leukemia&#xD;
&#xD;
                    -  Chronic or accelerated phase&#xD;
&#xD;
               -  Any of the following myelodysplastic syndromes:&#xD;
&#xD;
                    -  Refractory anemia (RA)&#xD;
&#xD;
                    -  RA with ringed sideroblasts&#xD;
&#xD;
                    -  RA with excess blasts NOTE: *&lt; 24% marrow blasts and &lt; 5% peripheral blood&#xD;
                       blasts (within 10 days of beginning conditioning regimen)&#xD;
&#xD;
          -  No secondary acute leukemia&#xD;
&#xD;
          -  Prior CNS tumor involvement allowed provided patient is asymptomatic and there is no&#xD;
             evidence of CNS disease on lumbar puncture and CT scan of the brain&#xD;
&#xD;
          -  Must have a 6/6 HLA-identical sibling donor available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 55&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT &lt; 10 times ULN&#xD;
&#xD;
          -  Hepatitis B core antigen, surface antigen, and e-antigen negative&#xD;
&#xD;
          -  Hepatitis B DNA negative&#xD;
&#xD;
          -  Hepatitis C RNA negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 50% by MUGA or echocardiogram&#xD;
&#xD;
          -  No right sided heart failure&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV_1 &gt; 50% of predicted&#xD;
&#xD;
          -  DLCO ≥ 50% of predicted (corrected for anemia)&#xD;
&#xD;
          -  Oxygen saturation ≥ 97% on room air&#xD;
&#xD;
          -  No pulmonary hypertension&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV-1 and 2 antibody negative&#xD;
&#xD;
          -  HIV-1 antigen negative&#xD;
&#xD;
          -  HTLV-I and II antibody negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  CNS function normal&#xD;
&#xD;
          -  No uncontrolled alcohol or substance abuse within the past 6 months&#xD;
&#xD;
          -  No other concurrent underlying medical condition that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 effective methods of contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior allogeneic or autologous hematopoietic stem cell transplantation&#xD;
&#xD;
          -  No concurrent medication to accelerate neutrophil or platelet engraftment except&#xD;
             filgrastim (G-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior solid organ transplantation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior investigational agents or devices&#xD;
&#xD;
          -  No other concurrent investigational agents or devices&#xD;
&#xD;
          -  No concurrent anti-infective therapy except prophylactic therapy&#xD;
&#xD;
          -  No other concurrent conditioning regimen agents&#xD;
&#xD;
          -  No concurrent herbal remedies except multivitamins&#xD;
&#xD;
          -  No other concurrent graft-versus-host disease prophylaxis medications (e.g.,&#xD;
             ursodeoxycholic acid)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary C. Territo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

